As vemurafenib is a US Food and Drug Administration (FDA)-approved serine/threonine kinase inhibitor, we investigated whether vemurafenib could restore some of the serine/threonine kinase-related signaling pathways and prevent disease progression in the dyW−/− mouse model of LAMA2-CMD. Here, MARK2 is linked to congenital muscular dystrophy.